>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • TMCI -35.8%, NTLA -29.6%, FOXF -25.8%, ASLE -24.2%, OPEN -23.8% (also dividend of tradable warrants), PSIX -20.4%, CLPT -18% (also to acquire IRRAS), AIRS -17.2%, EVCM -15.4% (also increases share repurchase authorization by $50 mln), OLED -15% (also to acquire OLED patent assets from Merck KGaA), XYZ -14.9%, CDXS -14.5% (also signs $37.8m supply assurance agreement with Merck), SG -14.1% (also to sell Spyce business), KRMN -13.6%, AAOI -12.7%, CNH -12.2%, ACHR -11.6% (also to acquire LA airport as strategic air taxi network hub and AI testbed; also raises $650 mln in offering of 81.25 mln shares at $8/sh), KRO -10.6%, GAU -9.4%, VERI -8.9%, RUN -8.7%, CRNX -8.5%, EXK -8.5%, USAR -8.3%, BL -7.6%, DOCS -7.3%, MP -6.7%, WSC -6.6%, OUT -6.4%, SMR -6.3% (also FLR reaches deal with SMR; will convert remaining Class B units of SMR into Class A shares and will promptly begin a structured monetization of shares), RXT -6.2%, TTWO -6.1% (also delays Grand Theft Auto VI release to Nov 2026), DKNG -5.9% (also increases share repurchase program to $2 bln), RLAY -5.7%, INDI -5.4% (also names new CFO), GRNT -5%, MRVI -4.8%, GPRO -4.7%, STNE -4.6%, DNN -4.5%, ASTH -4.4%, ONTO -4.4%, CC -4.4%, CEG -4.1%, AMRK -4% (also to change name and ticker to Gold.com under the ticker "GOLD"; also to acquire Monex Precious Metals), ARLO -3.8%, MCHP -3.5%, TRUP -3.5%, SOUN -3.4%, LION -3.3%, LMAT -3%, ESNT -2.9%, PCRX -2.8%, IREN -2.7%, AVPT -2.3%, GTN -2.2%, ENB -1.9%, CDTX -1.7%, HMC -1.7%, CERT -1.6%, PTGX -1.6%, TXRH -1.4%, AGO -1% (also increases share repurchase authorization by $100 mln)
Other news:
  • ELDN -45.4% (presents Phase 2 BESTOW trial results for Tegoprubart)
  • SGHT -10% (names new CFO and new COO)
  • BHST -8.6% (stock offering)
  • IONQ -3.7% (selected for Stage B of DARPA Quantum Benchmarking Initiative)
  • ALT -3.2% (files for $400 mln mixed securities shelf offering)
  • ALT -3.2% (entered into $200 mln Equity Distribution Agreement with Leerink)
  • SHC -2.2% (30 mln share offering)
  • VOYG -2.1% (prices offering of $435.0 mln of 0.75% convertible senior notes due 2030)
  • WFG -1.6% (to close 2 lumber mills)
  • JOBY -1.6% (to sell EV aircraft and services valued at up to $250 mln to Alatau Advance)

>>> Fed Vice Chair Phillip Jefferson gives speech on economy and AI

Fed Vice Chair Phillip Jefferson gives speech on economy and AI
  • "AI can allow a worker to complete tasks in moments that previously took many minutes, if not hours. That has caused many to question whether AI will lead to notable job loss. This potential disruption of labor is a real risk. By automating certain tasks, it could lead to a reduction in some types of jobs. But increased productivity leads to economic growth, which may create new employment opportunities. AI is also expected to create new job categories and transform existing ones. There has been robust competition among high-tech firms for workers who possess the skills to develop this technology.7
  • Many have legitimate concerns that AI will cause job loss. At least for certain firms and workers in certain occupations, this is likely to be true. There are many examples where transformative technologies, such as the personal computer, did cause some workers to lose their jobs, but we also saw new industries and occupations emerge because of the innovation. Indeed, some large employers have recently indicated they are lowering overall hiring plans in light of advances in AI and other forms of automation.8 Some research has also suggested that AI is having a more detrimental effect on the job prospects of younger, less experienced workers, including recent graduates, relative to those further along in their careers.9 The net effect on employment is highly uncertain and may show variation across industries and occupations over time. For the overall economy, one way to think about AI-related job losses—at least until it creates new jobs—is that it can create economic slack. In a world where firms only deployed AI to replace existing workers, even at a lower level of overall employment, the productive capacity of the economy has increased (or stayed the same). Of course, if people seamlessly get redeployed to more productive tasks, the economy produces more without any additional slack—more on this soon. Whether AI substitutes for labor or complements it is an important question that requires continued study.
  • Now having discussed the policy implications of AI, I would like to briefly update you about my current outlook for the U.S. economy. While federal statistical agencies are largely not producing data during the government shutdown, data available from other sources suggest that the overall economic picture in the U.S. has not changed much over the past few months. The economy has been growing at a moderate pace while labor market conditions appear to be consistent with a gradually cooling. Inflation is running at a rate similar to that of a year ago. The lack of progress on headline inflation appears to be due to tariff effects, with signs that underlying inflation may be continuing to make progress to 2 percent. Market-based long-term inflation expectations continue to be well-anchored. I remain firmly committed to returning inflation to the Fed's 2 percent target.
  • I supported last week's decision to reduce our policy rate by a quarter percentage point. That step was appropriate because I see the balance of risks as having shifted in recent months as downside risks to employment have increased. The current policy stance is still somewhat restrictive, but we have moved it closer to its neutral level that neither restricts nor stimulates the economy. Given this, it makes sense to proceed slowly as we approach the neutral rate.
  • With respect to the path of the policy rate going forward, I will continue to determine policy based on the incoming data, the evolving outlook, and the balance of risks. I always take a meeting-by-meeting approach. This approach is especially prudent because it is unclear how much official data we will have before our December meeting."

Full speech :
Thank you, President Nagel and the Bundesbank, for the opportunity to meet with you today.1 I am excited to be here. I cherish opportunities to talk with groups of young people such as this. I spent most of my career as a professor and university administrator. I am glad to return to those roots a bit today. I will make sure I leave plenty of time for questions. But I would like to start by speaking with you about a topic that's been on my mind, and I bet it has been on many of yours: artificial intelligence (AI).
Often, when I gather with students, consumers, or businesspeople, the conversation quickly turns to AI. And it is easy to understand why—you do not even need to ask a chatbot! AI has the potential to transform how we work and how we live, and it could have a profound effect on the economy. Today, I will talk about AI's rapid growth and how I approach thinking about AI by examining it through the lens of the dual mandate given to the Federal Reserve by the U.S. Congress. That mandate instructs America's central bank to pursue maximum employment and price stability. I will describe the effects that AI may have on both sides of that mandate. Finally, I will briefly update you on my economic outlook before turning to your questions.
AI's Rapid Growth
In a few short years, AI morphed from the realm of science fiction to a tool that high schoolers use to help them do their science homework! Seriously, it is amazing to see school children use AI to generate quizzes to prepare for exams, home chefs use it to create recipes for a wholesome dinner, and jobseekers use it to consider career tradeoffs, among many other purposes. Consumer use of AI has grown rapidly, and it is integrated into a multitude of existing products, including search engines, phones, and vehicles.
As of last month, ChatGPT, which is just one of a growing number of generative AI models, is used by more than 800 million people every week, an increase from 500 million a week at the end of March.2 Enterprise use of AI has been growing too. A recently released study showed that the proportion of Americans using AI at their jobs has also been growing at a fast clip. Researchers found that workers' adoption of generative AI rose from 30.1 percent as of December 2024 to 45.9 percent as of June and July of this year.3 And among survey respondents who had adopted AI tools, about a third said they use them daily. That same study found that AI is most used at jobs by younger, more highly educated, and higher-earning workers and that productivity for workers increased substantially when using AI tools.
There is strong evidence that AI can increase labor productivity in various industries and occupations. For example, a paper from Stanford economist, Erik Brynjolfsson, and coauthors showed the effects of AI implementation among customer support agents.4 They found that AI tools increased productivity—as measured by issues resolved per hour—14 percent, on average, and the improvement in productivity for novice and low-skilled employees was much larger.
AI is also advancing productivity in highly technical scientific research. Take protein folding, for example. Proteins are the building blocks of the human body and life itself. They assume an almost infinite variety of shapes. Predicting those shapes—which determine their function—is vital for understanding how cells and diseases work and for finding drugs to treat them. Just five years ago, scientists had a good understanding of the structures of just 17 percent of the roughly 20,000 proteins in the human body.5 For each protein, that knowledge was earned through months or years of hard work and a potential cost of tens of thousands of dollars or more. Thanks to the development of the AlphaFold model, an AI system that predicts a protein's structure, scientists now know the structures of all the proteins in the human body—and some 200 million more.6
More broadly, like many others, I see the promise for AI technology to be transformative, perhaps in ways as dramatic as past technological achievements, such as the printing press, steam engine, and the Internet, which are known as general purpose technologies for their wide-ranging effects.
Labor Market and Prices
When I think about this technology, I consider how it will affect both sides of the Fed's dual mandate of promoting maximum employment and stable prices. As such, it is something that economists and policymakers must monitor.
AI can allow a worker to complete tasks in moments that previously took many minutes, if not hours. That has caused many to question whether AI will lead to notable job loss. This potential disruption of labor is a real risk. By automating certain tasks, it could lead to a reduction in some types of jobs. But increased productivity leads to economic growth, which may create new employment opportunities. AI is also expected to create new job categories and transform existing ones. There has been robust competition among high-tech firms for workers who possess the skills to develop this technology.7
Many have legitimate concerns that AI will cause job loss. At least for certain firms and workers in certain occupations, this is likely to be true. There are many examples where transformative technologies, such as the personal computer, did cause some workers to lose their jobs, but we also saw new industries and occupations emerge because of the innovation. Indeed, some large employers have recently indicated they are lowering overall hiring plans in light of advances in AI and other forms of automation.8 Some research has also suggested that AI is having a more detrimental effect on the job prospects of younger, less experienced workers, including recent graduates, relative to those further along in their careers.9 The net effect on employment is highly uncertain and may show variation across industries and occupations over time. For the overall economy, one way to think about AI-related job losses—at least until it creates new jobs—is that it can create economic slack. In a world where firms only deployed AI to replace existing workers, even at a lower level of overall employment, the productive capacity of the economy has increased (or stayed the same). Of course, if people seamlessly get redeployed to more productive tasks, the economy produces more without any additional slack—more on this soon. Whether AI substitutes for labor or complements it is an important question that requires continued study.
On the other side of our dual mandate, price stability, AI could help the economy achieve higher growth through increased productivity while reducing inflationary pressures. Specifically, increased productivity could lower production costs and put downward pressure on prices. Not only could AI allow a specific worker to be more efficient in their day-to-day tasks, but it also has the potential to allow for better thinking around complex problems—for example, in logistics and transportation. More efficient allocation of resources as well as potential improvements in supply chains could reduce associated costs, leading to lower prices for various goods and services. Conversely, AI could put upward pressure on certain price categories as many firms push to scale up the technology. I mentioned the rising wages for certain workers with skills that complement AI. AI technology also requires data centers, which compete with other production processes for land, energy, and other inputs. So, I think that AI's effect on inflation is not solely downward pressure.
Implications on monetary policy
So, what do these still-developing labor and price effects mean for monetary policy? The short answer is that it is likely still too soon to tell. As always, policymakers confront the challenge of sorting out changes in the economy that are due to cyclical factors from those resulting from structural change, which AI may well represent. Some of the recent changes in hiring patterns, productivity growth, and inflation are likely to represent AI-driven change, but it is difficult to know the degree.
Productivity gains from AI may affect the relationship between employment and inflation and hence the conduct of monetary policy. For example, a productivity-induced boost to the growth rate of potential output could imply that monetary policy will not need to react strongly to what would have previously been perceived as tightness in the labor market.
The uncertain implications of AI for employment and inflation could take some time to filter broadly through economy. Also, AI's effects will likely vary across different industries and regions of both the U.S. and the world. And monetary policy decisions need to be made with a broad view of what is happening in the economy, not just in one sector or technology. There is still much to learn. I counsel exercising humility about the challenges in predicting AI's effects on employment and inflation. Policymakers, businesses, and individuals should remain flexible and prepared to adapt as the effects of AI continue to unfold.
Economic Outlook
Now having discussed the policy implications of AI, I would like to briefly update you about my current outlook for the U.S. economy. While federal statistical agencies are largely not producing data during the government shutdown, data available from other sources suggest that the overall economic picture in the U.S. has not changed much over the past few months. The economy has been growing at a moderate pace while labor market conditions appear to be consistent with a gradually cooling. Inflation is running at a rate similar to that of a year ago. The lack of progress on headline inflation appears to be due to tariff effects, with signs that underlying inflation may be continuing to make progress to 2 percent. Market-based long-term inflation expectations continue to be well-anchored. I remain firmly committed to returning inflation to the Fed's 2 percent target.
I supported last week's decision to reduce our policy rate by a quarter percentage point. That step was appropriate because I see the balance of risks as having shifted in recent months as downside risks to employment have increased. The current policy stance is still somewhat restrictive, but we have moved it closer to its neutral level that neither restricts nor stimulates the economy. Given this, it makes sense to proceed slowly as we approach the neutral rate.
With respect to the path of the policy rate going forward, I will continue to determine policy based on the incoming data, the evolving outlook, and the balance of risks. I always take a meeting-by-meeting approach. This approach is especially prudent because it is unclear how much official data we will have before our December meeting.
Before I turn to your questions, let me conclude by saying that this is an exciting time. It feels like we are at the dawn of a new age—an age your generation will shape and see come to its full maturity. By the end of your careers, many of you will take on tasks and accomplish feats you cannot even imagine at this moment, and AI technology may well be part of that progress.
Thank you again for having me. It is an honor to be here. I am looking forward to our discussion.

1. The views expressed here are my own and are not necessarily those of my colleagues on the Federal Reserve Board or the Federal Open Market Committee. Return to text
2. Rebecca Bellan (2025), "Sam Altman Says ChatGPT Has Hit 800m Weekly Active Users," TechCrunch, October 6, https://techcrunch.com/2025/10/06/sam-altman-says-chatgpt-has-hit-800m-weekly-active-users/. Return to text
3. Jonathan Hartley, Filip Jolevski, Vitor Melo, and Brendan Moore (2024), "The Labor Market Effects of Generative Artificial Intelligence," unpublished paper, available at SSRN: http://dx.doi.org/10.2139/ssrn.5136877. Return to text
4. Erik Brynjolfsson, Danielle Li, and Lindsey R. Raymond (2023), "Generative AI at Work," NBER Working Paper Series 31161 (Cambridge, Mass.: National Bureau of Economic Research, April; revised November 2023). Return to text
5. Eduard Porta-Pardo, Victoria Ruiz-Serra, Samuel Valentini, and Alfonso Valencia (2022), "The Structural Coverage of the Human Proteome Before and After AlphaFold," PLoS Comput Biol., vol. 18 (1), January 24. Return to text
6. EMBL-EBI (2023), "AlphaFold Protein Structure Database," webpage, https://alphafold.ebi.ac.uk/. Return to text
7. Meghan Bobrowsky, Berber Jin, and Ben Cohen (2025), "Zuckerberg Leads AI Recruitment Blitz Armed With $100 Million Pay Packages," Wall Street Journal, June 22. Return to text
8. For example, see Tom Huddleston Jr. (2025), "Walmart CEO: 'AI Is Literally Going to Change Every Job'—How The Best Employees Can Still Stand Out," CNBC, September 29; and Karen Weise (2025), "Amazon Plans to Replace More Than Half a Million Jobs With Robots," New York Times, October 21. Return to text
9. J.P. Morgan (2025), "AI's Impact on Job Growth," webpage, https://www.jpmorgan.com/insights/global-research/artificial-intelligence/ai-impact-job-growth.

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • GMED +27.6%, FROG +21.9%, PCT +20.7%, ORGO +19.8%, TNDM +16.3%, LASR +15.4%, FIGS +15%, CGC +14.7%, EXPE +14.6%, ICUI +14.1%, TXG +13%, KRUS +12.4%, QNST +11.8% (also authorizes new $40 mln share repurchase program), PAR +11.4%, WLDN +11.4%, EVH +11.3% (also unveils innovative model seeking to improve cancer care), GCT +10.5%, AFRM +10.2%, ABL +9.5% (also initiates annual dividend), GRND +9.1%, G +8.8%, FLR +8.5% (also, FLR reaches deal with SMR; will convert remaining Class B units of SMR into Class A shares and will promptly begin a structured monetization of shares), FNKO +8.3%, EXPI +8.1%, AMN +8%, KODK +7.9%, INOD +7.9% (also launches Innodata Federal), XPOF +7%, CE +6.8%, AKAM +6.6%, WEN +6.6%, IBEX +6.4%, OS +6.2%, PGNY +5.6%, CARL +5.5%, BILL +5.3%, PTON +5.2%, HCI +5.1%, FLGT +5.1%, MNST +4.8%, NRDS +4.8%, KKR +4.8%, AMPX +4.4%, PLMR +4.4%, CENX +4.2%, SNDK +4.2%, FLO +4.1%, TCX +4% (also names new CEO), NKTR +4%, CLMT +3.8%, ABNB +3.7%, ZD +3.5%, TTD +3.4%, MKTX +3.4%, MWA +3.3% (also CEO to retire, names new CEO), NTRA +3.3%, ATMU +3.2%, FIVN +3.1% (also $150 mln buyback auth, inclusive of $50 mln ASR), NNI +2.5%, DIOD +2.3%, VCTR +2.1%, GEN +2.1%, OMDA +2%, CPK +2%, SLVM +2%, NOG +1.9%, ED +1.8%, AHR +1.8%, ALRM +1.8%, BHF +1.7%, CIVI +1.6%, HUN +1.5% (also decreases dividend), GSAT +1.5%, RBA +1.4%, AQN +1.4%, ANIP +1.4%, PLUS +1.3%, TU +1.3%, DBX +1.2%, CARG +1.2%, BAM +1.2%, WPM +1.1% (also acquires Gold Stream on the Spring Valley Project), EOG +1.1%, AORT +1.1%, HRB +1.1%, BIP +1%, UI +1%,
Other news:
  • ORIC +7.3% (announces publication of research paper)
  • BW +4.5% (raised $67.5 mln including approximately $50 mln from a single fundamental global institutional investor, through its ATM offering that opened on November 5, 2025)
  • RRR +3.4% (to join S&P SmallCap 600)
  • AKBA +3% (Vafseo data analysis)
  • BEN +2.2% (partnership with Wand AI)
  • EMBJ +1.2% (approves share buyback program)
  • INTC +1% (Elon Musk says TSLA may discuss AI chip production with co, according to Barron's)

>>> US Research Calls I

Research Calls I
  • Upgrades
    • 4D Molecular Therapeutics (FDMT) upgraded to Equal Weight from Underweight at Morgan Stanley
    • ArcelorMittal (MT) upgraded to Overweight from Neutral at JPMorgan
    • ASML (ASML) upgraded to Buy from Neutral at Rothschild & Co Redburn
    • Aurinia Pharmaceuticals (AUPH) upgraded to Buy from Hold at Jefferies, tgt $21
    • Black Hills (BKH) upgraded to Outperform from Sector Perform at Scotiabank, tgt $81
    • Champion Homes (SKY) upgraded to Outperform from Neutral at Zelman, tgt $79.25
    • Datadog (DDOG) upgraded to Overweight from Sector Weight at KeyBanc, tgt $230
    • Expedia (EXPE) upgraded to Neutral from Underweight at Piper Sandler, tgt $250
    • First Northwest Bancorp (FNWB) upgraded to Overweight from Neutral at Piper Sandler, tgt $13.50
    • Globus Medical (GMED) upgraded to Buy from Neutral at BofA Securities, tgt $91
    • Globus Medical (GMED) upgraded to Buy from Hold at Truist, tgt $93
    • Host Hotels (HST) upgraded to Buy from Neutral at Compass Point, tgt $22
    • JFrog (FROG) upgraded to Outperform from Perform at Oppenheimer, tgt $75
    • Matson (MATX) upgraded to Outperform from Peer Perform at Wolfe Research, tgt $142
    • Middleby (MIDD) upgraded to Neutral from Underweight at JPMorgan, tgt $125
    • Penn Entertainment (PENN) upgraded to Buy from Hold at CBRE, tgt $18
    • Penn Entertainment (PENN) upgraded to Buy from Hold at Stifel, tgt $21
    • TC Energy (TRP) upgraded to Outperform from Market Perform at BMO Capital
    • The Trade Desk (TTD) upgraded to Buy from Hold at Benchmark, tgt $65
    • Unity Software (U) upgraded to Outperform from Neutral at Macquarie, tgt $50
  • Downgrades
    • AbCellera Biologics (ABCL) downgraded to Market Perform from Outperform at Leerink, tgt $4
    • Americold Realty Trust (COLD) downgraded to In Line from Outperform at Evercore ISI, tgt $13
    • BlackLine (BL) downgraded to Neutral from Outperform at Robert W. Baird, tgt $55
    • CarMax (KMX) downgraded to Sector Perform from Outperform at RBC Capital
    • Cogent Communications (CCOI) downgraded to Equal Weight from Overweight at Wells Fargo, tgt $27
    • DENTSPLY SIRONA (XRAY) downgraded to Market Perform from Outperform at William Blair
    • Intellia Therapeutics (NTLA) downgraded to Underweight from Neutral at JPMorgan, tgt $5
    • Penn Entertainment (PENN) downgraded to Hold from Buy at Needham
    • Sangamo BioSciences (SGMO) downgraded to Equal Weight from Overweight at Barclays, tgt $1
    • Sweetgreen (SG) downgraded to Market Perform from Outperform at William Blair
    • Teads Holding (TEAD) downgraded to Market Perform from Outperform at Citizens JMP
    • Treace Medical Concepts (TMCI) downgraded to Neutral from Buy at BTIG
    • Treace Medical Concepts (TMCI) downgraded to Underweight from Neutral at JPMorgan, tgt $5
  • Others
    • Aardvark Therapeutics (AARD) initiated with a Buy at BTIG, tgt $26
    • ConnectOne Bancorp (CNOB) assumed with an Overweight at Piper Sandler, tgt $28
    • Foghorn Therapeutics (FHTX) initiated with a Buy at Guggenheim, tgt $12
    • Immunic (IMUX) initiated with a Buy at Roth Capital, tgt $3

>>> Europe : Brokers Upgrades & Downgrades - 7th of November 2025 V3(++)

>>> Up
* AMD Raised to Outperform at CICC; PT $265
* ArcelorMittal Raised to Overweight at JPMorgan; PT 42 euros
* ArcelorMittal ADRs PT Raised to $44 from $36 at Deutsche Bank (++)
* ASML Raised to Buy at Rothschild & Co Redburn; PT 1,200 euros
* Autostore Raised to Buy at Nordea; PT 14 kroner
* Baidu ADRs Raised to Buy at Deutsche Bank
* Boliden Raised to Outperform at RBC; PT 500 kronor
* BPER Banca Raised to Buy at Kepler Cheuvreux; PT 11.90 euros (++)
* British Land Raised to Buy at UBS; PT 435 pence (++)
* Cellnex Raised to Neutral at New Street Research; PT 29 euros
* DNO Raised to Buy at DNB Carnegie (++)
* Exel Composites Raised to Buy at OP Corporate Bank (++)
* Expedia PT Raised to $310 from $265 at Benchmark (++)
* Hexagon Raised to Outperform at BNPP Exane; PT 130 kronor
* Logista Raised to Neutral at Alantra Equities; PT 31.80 euros
* Maersk Raised to Hold at Arctic Securities; PT 11,900 kroner
* Optomed Raised to Buy at Inderes; PT 5.20 euros
* Paragon Raised to Buy at Shore Capital; PT 1,000 pence (++)
* Redeia Raised to Buy at JB Capital Markets; PT 18.30 euros
* Salmar Raised to Buy at Danske Bank Markets (++)
* Salzgitter Raised to Neutral at JPMorgan; PT 28.50 euros
* Seadrill Raised to Buy at SEB Equities; PT $34
* Uniper Raised to Neutral at Oddo BHF; PT 31 euros (+)
* Veidekke Raised to Buy at ABG; PT 185 kroner
* Voestalpine Raised to Overweight at JPMorgan; PT 40.60 euros

>>> Down
* Aixtron Cut to Sell at Van Lanschot Kempen; PT 15 euros
* AKWEL SADIR Cut to Hold at Portzamparc; PT 11.90 euros (+)
* ASM Intl Cut to Neutral at Rothschild & Co Redburn; PT 610 euros
* Banca Mediolanum Cut to Neutral at Banca Akros (+)
* BKW Cut to Neutral at UBS; PT 185 Swiss francs (++)
* Brembo Cut to Neutral at Intesa Sanpaolo; PT 11.20 euros (+)
* Daimler Truck Cut to Sell From Hold by MWB Research, Target Cut to EUR30.00 From EUR34.00 (++)
* DiaSorin Cut to Hold at Deutsche Bank; PT 71 euros
* EDP SA Cut to Sell at Goldman; PT 4.05 euros
* EDP Renovaveis Cut to Neutral at Goldman; PT 13.50 euros
* Elica Cut to Neutral at Intesa Sanpaolo; PT 1.80 euros
* Harvia Cut to Reduce at Inderes; PT 43 euros
* Kion Cut to Hold at DZ Bank; PT 63 euros
* Koenig & Bauer Cut to Reduce at Kepler Cheuvreux; PT 10 euros (++)
* Novo Cut to Sell at Intron Health; PT 270 kroner (+)
* OCI Cut to Hold at Kepler Cheuvreux; PT 3.70 euros (++)
* PZU Cut to Hold at Erste Group; PT 62.70 zloty (+)
* Sainsbury Cut to Reduce at Kepler Cheuvreux; PT 336 pence (++)
* Securitas Cut to Hold at Nordea
* SES GDRs Cut to Underweight at New Street Research
* UBS Cut to Underperform at KBW; PT 31 Swiss francs
* Weir Group Cut to Neutral at Goldman; PT 2,900 pence

>>> Initiation
* Avon Technologies Reinstated Buy at Investec; PT 2,300 pence (+)
* Circus Rated New Overweight at Cantor; PT 40.60 euros
* Stora Enso Rated New Neutral at SB1 Markets; PT 10.80 euros

>>> Call
* ArcelorMittal, Voestalpine Now JPMorgan’s Top Europe Steel Picks
* Boliden Nearing Inflection Point, Raised to Outperform at RBC (+)
* UBS Downgraded at KBW on Regulatory, Litigation Risks (+)
* UPM-Kymmene Double-Downgraded at JPMorgan, on Negative Watch (+)

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • GMED +31.2%, ORGO +29.6%, FROG +29.6%, FIGS +19.3%, TNDM +17.9%, EXPE +15.8%, GCT +15.4%, PCT +15.2%, ABL +14.2%, ICUI +14.1%, TXG +13.8%, XPOF +13.7%, LASR +13.3%, KRUS +12.4%, QNST +11.8%, WLDN +11%, EVH +10.5%, AFRM +10.2%, FLR +10%, FLR +10%, GRND +9.3%, FNKO +9.3%, INOD +8.9%, G +8.8%, AMPX +8.3%, PAR +8.2%, EXPI +8.1%, PTON +7.3%, AMN +7%, OS +6.9%, CE +6.6%, AKAM +6.4%, NRDS +6.4%, IBEX +6.4%, RBA +6.3%, BILL +6%, PGNY +5.6%, CARL +5.5%, KODK +5.3%, HCI +5.1%, MODG +4.6%, AHR +4.3%, NKTR +4.3%, SNDK +4.3%, ABNB +4.2%, PLMR +4.1%, TCX +4%, ORIC +3.9%, HUN +3.8%, CENX +3.6%, AKBA +3.5%, ZD +3.5%, RRR +3.4%, NTRA +3.4%, SOLV +3.3%, MWA +3.3%, AORT +3.2%, CON +3.2%, FIVN +3.1%, CIVI +3%, FLO +3%, GSAT +2.9%, TTD +2.8%, MNST +2.8%, NNI +2.5%, GEN +2.4%, DIOD +2.3%, BEN +2.2%, VCTR +2.1%, CPK +2%, NOG +1.9%, BHF +1.8%, ED +1.8%, ALRM +1.8%, AFCG +1.6%, URGN +1.5%, OMDA +1.4%, EMBJ +1.3%, PLUS +1.3%, DBX +1.2%, JANX +1.2%, CARG +1.2%, INTC +1.1%, HRB +1.1%, Q +1%
  • Gapping down:
    • ELDN -51.2%, TMCI -36.9%, NTLA -28.6%, FOXF -26.2%, EVCM -24%, OPEN -22.9%, PSIX -22.5%, SG -16.8%, CLPT -15.4%, OLED -15%, AAOI -14.9%, KRMN -14.6%, XYZ -14.4%, ASLE -14.3%, ACHR -12.2%, CDXS -10.6%, KRO -10.6%, SGHT -10%, LION -9.7%, USAR -9.6%, DKNG -9.2%, RXT -8.9%, MRVI -8.7%, BHST -8.6%, GAU -8.1%, MP -7.8%, DOCS -7.2%, STNE -6.9%, RUN -6.8%, WSC -6.6%, OUT -6.4%, VERI -6.3%, SMR -5.9%, GTN -5.2%, ZYME -5.1%, GRNT -5%, TTWO -4.9%, HASI -4.7%, ASTH -4.6%, SOUN -4.4%, GPRO -4.1%, IREN -4.1%, CRNX -4%, AMRK -4%, BL -3.9%, DNN -3.9%, CC -3.8%, RLAY -3.5%, ARLO -3.3%, INDI -3.2%, MCHP -3.1%, VOYG -3%, LMAT -3%, IONQ -2.9%, YELP -2.8%, PCRX -2.8%, AVPT -2.3%, SHC -2.2%, TRUP -2%, ALT -1.8%, PTGX -1.8%, HMC -1.8%, CDTX -1.7%, ONTO -1.7%, WFG -1.6%, CERT -1.6%, PBA -1.6%, SNA -1.2%, JOBY -1.1%, TXRH -1.1%, AGO -1%

>>> CNH Industrial misses by $0.05, beats on revs; lowers FY25 EPS below consens

CNH Industrial misses by $0.05, beats on revs; lowers FY25 EPS below consensus (10.26 -0.21)
  • Reports Q3 (Sep) earnings of $0.08 per share, excluding non-recurring items, $0.05 worse than the FactSet Consensus of $0.13; revenues fell 5.5% year/year to $4.4 bln vs the $4.26 bln FactSet Consensus.
  • Co issues lowered guidance for FY25, sees EPS of $0.44-0.50 from $0.50-0.70 vs. $0.58 FactSet Consensus. Guidance Details: Agriculture segment net sales down between 11% and 13% year-over-year, with no currency translation effects. Agriculture segment adjusted EBIT margin between 5.7% and 6.2%. Construction segment net sales down between 3% and 5% year-over-year, with no currency translation effects. Construction segment adjusted EBIT margin between 1.7% and 2.2%. Free cash flow of Industrial Activities(5) between $200 million and $500 million.
  • "While the current trade environment remains challenging for our farmers and builders, CNH continues to take decisive actions to navigate near-term headwinds. We are maintaining disciplined production levels, reducing channel inventories, investing in technology, and driving operational excellence. Our commitment to quality and innovation is unwavering, as demonstrated by recent product launches and industry recognition. Looking ahead, we remain focused on achieving our long-term strategic targets. I am confident that the steps we are taking will position CNH for renewed growth and success as market conditions improve."

>>> Alphabet discloses updated portfolio positions in 13F filing: New BBOT FIG p

Alphabet discloses updated portfolio positions in 13F filing: New BBOT FIG positions, Lowered MTSR holding

Highlights from Q3 2025 filing as compared to Q2 2025 (all amounts are approximate):
  • New: BBOT (2.82 mln shares), FIG (0.22 mln)
  • Increased: PRME (16.56 mln shares from 15.06 mln)
  • Maintained: PL (31.94 mln shares), FRSH (16.21 mln), ASTS (8.94 mln), PATH (7.03 mln), RVMD (4.13 mln), GTLB (2.72 mln), MAZE (2.41 mln), ARM (1.96 mln), TEM (1.55 mln), DXCM 1 mln)
  • Decreased: MTSR (3.78 mln shares from 4.96 mln shares)

>>> ZEAL DC — Amylin Reset: LLY Sets the Bar, Street Polarized Between Threat an

ZEAL DC — Amylin Reset: LLY Sets the Bar, Street Polarized Between Threat and Validation (Nov 2025)
Context:
Lilly’s eloralintide Ph2 data (16–20% WL @48w) landed at the top end of expectations. Tolerability benign — vomiting < GLP-1s, psychiatric AEs ≈ placebo, fatigue the only standout. ZEAL dropped –11% on cross-read fears for petrelintide. The market now splits between “LLY just killed the trade” and “LLY just proved the class works.”

BNP Paribas Exane – Validation, Not Threat (Outperform, TP DKK 905, +90%)
Exane frames the LLY data as mechanistic validation rather than competitive damage.
Fatigue and headache rates at LLY leave scope for Petrelintide to differentiate on tolerability.
Maintains ~⅓ of DCF from Petrelintide; plays 2026 catalysts (Petrelintide Ph2 Q1, Survodutide Ph3 mid-year).
Read-through: Buy-the-fear setup; safety optionality still under-owned.

Jefferies – “LLY Owns the Space Until Proven Otherwise” (Neutral)
Acknowledges amylin validation but argues Zealand is boxed-in.
LLY’s dose escalation works; its distribution, combo pipeline, and payer leverage give it portfolio gravity.
ZEAL must print optically superior data (~20 % WL, visibly cleaner AE profile) to regain relevance.
Read-through: Dead money until data; LLY dominance defines the trade.

J.P. Morgan – Bar Raised, Read-Across Negative (Neutral)
Highlights eloralintide’s 16–20 % WL and tolerability on par with placebo.
Argues ZEAL’s dual amylin + calcitonin mechanism brings no clear benefit and possible extra GI risk.
Read-through: Benchmark raised; differentiation narrative undermined.

Goldman Sachs – “Risk Priced, Optionality Mispriced” (Buy, TP DKK 866, +104 %)
Calls the –11 % move an overreaction.
LLY’s data crystallise a known risk but confirm amylin validity.
Fatigue absent in Petrelintide Ph1, nausea milder, and gender skew makes data non-comparable.
Highlights 2026 catalyst stack (Petrelintide Ph2 + Survodutide Ph3) as a re-rating window.
Read-through: Mechanism validated; ZEAL volatility mispriced; convex upside into 2026.

Barclays – “Bar Set High But Still Room for Petrelintide” (Overweight)
Notes eloralintide “sets the bar high” but sees space for Petrelintide to achieve 15–20 % WL with a clean safety profile.
Maintains Overweight rating; sees near-term volatility as noise.
Read-through: Balanced optimism — LLY leads, but ZEAL’s clean safety thesis keeps it relevant.

Investment Implications
  • LLY defines the ceiling (~20 % WL, mild AEs) but validates the mechanism.
  • BNP / GS / Barclays: constructive camp — mechanism proven, sell-off excessive, safety differentiation intact.
  • Jefferies / JPM: defensive camp — LLY’s scale and data dominance cap ZEAL’s re-rating potential until 1H ’26.
  • Core trade logic: Petrelintide Ph2 is now the single binary catalyst — confirm GLP-1-like efficacy without fatigue or GI drag, and ZEAL rerates 50 % +.
Desk line: LLY set the benchmark; GS and Barclays say that bar doesn’t erase the story — it defines the risk premium.

Sources: BNP Paribas Exane (6 Nov 25) · Jefferies (Comment Nov 25) · J.P. Morgan (Obesity Week 2025) · Goldman Sachs (7 Nov 25, Sharma et al.) · Barclays (Lisa Pham, Bloomberg 7 Nov 25).